- China’s COVID-19 vaccine by Sinovac shows 67% efficacy in Chile study.
- Chile’s study examined CoronaVac’s effectiveness among 10.5 million people.
- The CoronaVac vaccine is said to have been 85% effective in preventing hospitalizations.
- The Chilean study looked at the impact of the vaccine among people in the public health system.
The Chilean government reported that China’s Sinovac COVID-19 vaccine was found to be 67% effective in preventing symptomatic infection.
According to the published data, the CoronaVac vaccine by the company was 85% effective in preventing hospitalizations and 80% effective in preventing deaths. It also added that the data should prove a “game changer” from the vaccine more widely.
Chile’s stock of CoronaVac is said to be running low. China has agreed the supply of an total of 14.2 million vaccine shots to Chile which will be fully delivered by late May.
Chile reported that the study examined CoronaVac’s effectiveness among 10.5 million people. It also looked again at people who had been vaccinated and those who had not. Vaccines were also said to be administered approximately 28 days apart.
The Chilean study looked at the impact of the vaccine among people in the public health system between Feb. 2-April 1, adjusting for age, sex, comorbidities, income and nationality.
It also compared people who were not inoculated, individuals 14 days or more after receiving one dose and more than 14 days after receiving a second dose. Protection against the virus was reported to be far higher after the second shot of the vaccine.